Pandemic/Padémique Medicago

Efficiency and rapidity

A true pioneer, Medicago’s mission since its inception in 1999 has been to provide a therapeutic response to pandemics. In 2009, the company produced an H1N1 vaccine candidate in 19 days.

Medicago then produced 10 million doses of a research-grade vaccine candidate against a specific strain of influenza in 30 days and demonstrated the ability to rapidly produce a research-grade anti-Ebola monoclonal antibody cocktail.

Since the start of the COVID-19 pandemic, governments, organizations, and people around the world have worked diligently to find solutions that will enable all of us to return to some sense of normalcy.

In the case of Medicago, the pandemic has served to accelerate research and development activities for a COVID vaccine using its proprietary plant-based platform.

Helping to improve public health

Medicago’s aspiration is to create an infrastructure that will allow us to provide a proven solution to address the current COVID-19 pandemic as well as future pandemics. At the same time, Medicago is building the knowledge and capacity to achieve its mission of helping to improve public health worldwide using the power of plants.